| pubmed-article:1334515 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1334515 | lifeskim:mentions | umls-concept:C0003873 | lld:lifeskim |
| pubmed-article:1334515 | lifeskim:mentions | umls-concept:C0081408 | lld:lifeskim |
| pubmed-article:1334515 | lifeskim:mentions | umls-concept:C1289971 | lld:lifeskim |
| pubmed-article:1334515 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:1334515 | pubmed:dateCreated | 1993-1-15 | lld:pubmed |
| pubmed-article:1334515 | pubmed:abstractText | The effects of zileuton, a new 5-lipoxygenase inhibitor, on leukotriene generation and clinical response in rheumatoid arthritis (RA) was studied in a 4-week randomized double blind placebo controlled study at 2 academic rheumatology centers. Zileuton decreased the mean (+/- SEM) ionophore induced synthesis of leukotriene B4 at Week 1 by 70% from 191.2 +/- 28.5 to 57.5 +/- 17.0 ng/ml. A parallel suppression of all major 5-lipoxygenase pathway products was observed. An improvement in clinical variables was observed in the zileuton and placebo treated population. No unique toxicity was identified in this study. Zileuton inhibited 5-lipoxygenase in RA with a suggestion of clinical response with limited toxicity. | lld:pubmed |
| pubmed-article:1334515 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1334515 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1334515 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1334515 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1334515 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1334515 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1334515 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1334515 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1334515 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1334515 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1334515 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1334515 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:1334515 | pubmed:issn | 0315-162X | lld:pubmed |
| pubmed-article:1334515 | pubmed:author | pubmed-author:SperlingRR | lld:pubmed |
| pubmed-article:1334515 | pubmed:author | pubmed-author:RubinPP | lld:pubmed |
| pubmed-article:1334515 | pubmed:author | pubmed-author:CoblynJ SJS | lld:pubmed |
| pubmed-article:1334515 | pubmed:author | pubmed-author:KremerJ MJM | lld:pubmed |
| pubmed-article:1334515 | pubmed:author | pubmed-author:HelfgottSS | lld:pubmed |
| pubmed-article:1334515 | pubmed:author | pubmed-author:WeinblattM... | lld:pubmed |
| pubmed-article:1334515 | pubmed:author | pubmed-author:PetrilloGG | lld:pubmed |
| pubmed-article:1334515 | pubmed:author | pubmed-author:HensonBB | lld:pubmed |
| pubmed-article:1334515 | pubmed:author | pubmed-author:MaierA LAL | lld:pubmed |
| pubmed-article:1334515 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1334515 | pubmed:volume | 19 | lld:pubmed |
| pubmed-article:1334515 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1334515 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1334515 | pubmed:pagination | 1537-41 | lld:pubmed |
| pubmed-article:1334515 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:1334515 | pubmed:meshHeading | pubmed-meshheading:1334515-... | lld:pubmed |
| pubmed-article:1334515 | pubmed:meshHeading | pubmed-meshheading:1334515-... | lld:pubmed |
| pubmed-article:1334515 | pubmed:meshHeading | pubmed-meshheading:1334515-... | lld:pubmed |
| pubmed-article:1334515 | pubmed:meshHeading | pubmed-meshheading:1334515-... | lld:pubmed |
| pubmed-article:1334515 | pubmed:meshHeading | pubmed-meshheading:1334515-... | lld:pubmed |
| pubmed-article:1334515 | pubmed:meshHeading | pubmed-meshheading:1334515-... | lld:pubmed |
| pubmed-article:1334515 | pubmed:meshHeading | pubmed-meshheading:1334515-... | lld:pubmed |
| pubmed-article:1334515 | pubmed:meshHeading | pubmed-meshheading:1334515-... | lld:pubmed |
| pubmed-article:1334515 | pubmed:meshHeading | pubmed-meshheading:1334515-... | lld:pubmed |
| pubmed-article:1334515 | pubmed:meshHeading | pubmed-meshheading:1334515-... | lld:pubmed |
| pubmed-article:1334515 | pubmed:meshHeading | pubmed-meshheading:1334515-... | lld:pubmed |
| pubmed-article:1334515 | pubmed:meshHeading | pubmed-meshheading:1334515-... | lld:pubmed |
| pubmed-article:1334515 | pubmed:meshHeading | pubmed-meshheading:1334515-... | lld:pubmed |
| pubmed-article:1334515 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1334515 | pubmed:articleTitle | Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis. | lld:pubmed |
| pubmed-article:1334515 | pubmed:affiliation | Department of Rheumatology/Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115. | lld:pubmed |
| pubmed-article:1334515 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1334515 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:1334515 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:1334515 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:1334515 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:1334515 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1334515 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1334515 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1334515 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1334515 | lld:pubmed |
